

CERTIFICATE OF MAILING

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED  
WITH THE UNITED STATES POSTAL SERVICE WITH SUFFICIENT POSTAGE  
AS FIRST-CLASS MAIL IN AN ENVELOPE ADDRESSED TO:  
COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450, ON



October 23, 2006  
Dioreen Halata  
ATTORNEY FOR APPLICANT  
10/23/06  
DATE

Attorney Docket No. B45187C1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Cohen, et al. October 23, 2006  
Serial No.: 10/789,758 Group Art Unit No.: 1645  
Filed: February 27, 2004 Examiner: N. Minnifield  
For: VACCINES

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Information Disclosure Statement Under 37 C.F.R. §1.97(c)

The attached list of citations is being submitted under the provisions of 37 C.F.R. §1.56 and §1.97 for consideration by the United States Patent and Trademark Office, prior to the granting of this patent. Their inclusion herein, however, should not be construed as an admission that any particular cited document is effective prior art or that it discloses or renders obvious any aspect of the claimed invention.

The documents cited herein are listed on the enclosed PTO Form 1449. A copy of each cited document is enclosed, except U.S. Patent documents, and those references which are already part of the filewrapper. This statement is being filed under the provisions of 37 C.F.R. §1.97(c), before the mailing date of a Final Office action or before the mailing date of a Notice of Allowance, along with authorization to charge the \$180.00 fee specified in 37 C.F.R. §1.17(p) to the Deposit Account No. 19-2570.


10/26/2006 WASFAW1 00000018 192570 10789758

03 FC:1806 180.00 DA

Serial No.: 10/789,758  
Group Art Unit No.: 1645

Please charge any additional fees under 37 C.F.R. §1.16 or §1.17 which may be required by this paper, or credit any overpayment, to the indicated Deposit Account.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Andrea V. Lockenour", written over the typed name.

Andrea V. Lockenour  
Attorney for Applicants  
Registration No. 51,962

GLAXOSMITHKLINE  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, PA 19406-0939  
Phone (610) 270-7568  
Facsimile (610) 270-5090

Form PTO-1449

U.S. Department of Commerce  
Patent and Trademark OfficeATTY. DOCKET NO.  
B45187C1SERIAL NO.  
10/789,758**INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT**

(Use several sheets if necessary)

APPLICANT  
Cohen, et al.FILING DATE  
February 27, 2004GROUP  
1645**U.S. PATENT DOCUMENTS**

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

**FOREIGN PATENT DOCUMENTS**

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
BA	EP0278940A2	25 Jan. 1988	Europe				

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent Pages, Etc.)

CA	Allouche, <i>et al.</i> , "Protective Efficacy of the RTS,S/AS02 <i>plasmodium falciparum</i> Malaria Vaccine is not Strain Specific," <i>Am. J. Trop. Med Hyg.</i> (2003) 68(1):97-101
CB	Ambroise-Thomas P., "Vaccination against malaria. Disappointments and hopes," <i>Bulletin de l'Academie nationale de medicine</i> (Nov. 1997) 181(8):167-48.
CC	Bojang, <i>et al.</i> , "Efficacy of RTS,S/AS02 malaria vaccine against <i>Plasmodium falciparum</i> infection in semi-immune adult men in The Gambia: a randomised trial," <i>The Lancet</i> (Dec. 8, 2001) 358:1927-1933.
CD	Burchmore, Richard, "Malaria vaccine," <i>Current Opinion in Anti-infective Investigational Drugs</i> (2000) 2(1):83-87.
CE	Genton and Corradin, "Malaria Vaccines: From the Laboratory to the Field," <i>Current Drug Targets Immune, Endocrine &amp; Metabolic Disorders</i> (2002) 2:255-267.
CF	Greenwood, <i>et al.</i> , "Malaria," <i>Lancet</i> (2005)365:1487-1498.
CG	Heppner, <i>et al.</i> , "Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress in the Walter Reed Army Institute of Research," <i>Vaccine</i> (2005)23:2243-2250.
CH	Heppner, <i>et al.</i> and Cohen <i>et al.</i> (GlaxoSmithKline Biologicals,) "Adjuvanted RTS,S and Other Protein-Based Pre-Erythrocytic Stage Malaria Vaccines," <i>New Generation Vaccines 3<sup>rd</sup> Edition</i> (2004):851-859.
CI	Pinder M. <i>et al.</i> , "Cellular immunity induced by the Recombinant <i>Plasmodium falciparum</i> Malaria Vaccine, RTS,S/AS02, in semi-immune adults in The Gambia," <i>Clin. Exp. Immunol.</i> (2004) 135:286-293.
CJ	Stoute, <i>et al.</i> , "Long-Term Efficacy and Immune Responses following Immunisation with the RTS, S Malaria Vaccine," <i>The Journal of Infectious Diseases</i> (Oct 1998) 178(4):1139-1144.
CK	Sun, <i>et al.</i> , "Protective Immunity Induced with Malaria Vaccine, RTS,S, is Linked to <i>Plasmodium falciparum</i> Circumsporozoite Protein-Specific CD <sup>4</sup> and CD <sup>8</sup> T Cells Producing IFN- $\gamma$ ," <i>The Journal of Immunology</i> (2003) 171:6961-6967.
CL	Wheeler, <i>et al.</i> , "A Th-1-Inducing Adjuvant MPL, Enhances Antibody Profiles in Experimental Animals Suggesting It Has the Potential to Improve the Efficacy of Allergy Vaccines," <i>Allergy Immunology</i> , 126(2)135-139 (2001), abstract only.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

IDS - 04/11/2006

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> ( Not for submission under 37 CFR 1.99)	Application Number		10789758
	Filing Date		2004-02-27
	First Named Inventor	Joseph Cohen	
	Art Unit	1645	
	Examiner Name	Nita M Minnifield	
	Attorney Docket Number	B45187 C1	

U.S. PATENTS							Remove	
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear		
	1							
If you wish to add additional U.S. Patent citation information please click the Add button.							Add	
U.S. PATENT APPLICATION PUBLICATIONS							Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear		
	1							
If you wish to add additional U.S. Published Application citation information please click the Add button.							Add	
FOREIGN PATENT DOCUMENTS							Remove	
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup> i	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T <sup>5</sup>
NMM	1	W002/38176	WO	A2	2002-05-16	GSK Biologicals		<input type="checkbox"/>
NMM	2	WO2004/037189	WO	A2	2004-06-04	GSK Biologicals		<input type="checkbox"/>
NMM	3	WO2006/029887	WO	A2	2006-03-23	GSK Biologicals		<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10789758
Filing Date	2004-02-27
First Named Inventor	Joseph Cohen
Art Unit	1645
Examiner Name	Nita M Minnifield
Attorney Docket Number	B45187 C1

If you wish to add additional Foreign Patent Document citation information please click the Add button

**NON-PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>5</sup>
NMM	1	Alonso, et al., "Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomized controlled trial." Lancet 364:1411-1420 (2004).	<input type="checkbox"/>
NMM	2	Nussenweig, RS and Zavala, F., "A Malaria Vaccine Based on Sporozoite Antigen" New England Journal of Medicine 336:128-130 (1997)	<input type="checkbox"/>
NMM	3	Van Der Perre, P and Berret, J. "Vaccine efficacy: winning the battle (not war) against malaria." Lancet 364:1380-1383 (2004)	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

**EXAMINER SIGNATURE**

Examiner Signature	/N. M. Minnifield/ (06/12/2006)	Date Considered	06/12/2006
--------------------	---------------------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> See Kind Codes of USPTO Patent Documents at [www.USPTO.GOV](http://www.USPTO.GOV) or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.

<b>Notice of References Cited</b>	Application/Control No. 10/789,758		Applicant(s)/Patent Under Reexamination COHEN ET AL.	
	Examiner N. M. Minnifield		Art Unit 1645	Page 1 of 3

**U.S. PATENT DOCUMENTS**

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
*	A	US-2006/0073171	04-2006	Cohen, Joseph	424/272.1
*	B	US-2006/0051372	03-2006	Vande Velde, Vincent	424/202.1
*	C	US-2005/0197308	09-2005	Dalton et al.	514/044
*	D	US-6,942,866	09-2005	Birkett, Ashley J.	424/268.1
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

**FOREIGN PATENT DOCUMENTS**

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N	EP 278940 A2	08-1988	EP	Cabazon et al	C12N 15/00
	O					
	P					
	Q					
	R					
	S					
	T					

**NON-PATENT DOCUMENTS**

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	Ambrose, Bulletin de l'Academie nationale de medicine, Nov. 1997, 181/8:1637-1648 abstract only
	V	Genton et al, Current Drug Targets--Immune, Endocrine & Metabolic Disorders, 2002, 2:255-267
	W	Stoute et al, Journal of Infectious Diseases, October 1998, 178/4:1139-1144
	X	Bojang et al, Lancet, December 2001, 358:1927-1934

\*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)  
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

<b>Notice of References Cited</b>	Application/Control No. 10/789,758	Applicant(s)/Patent Under Reexamination COHEN ET AL.	
	Examiner N. M. Minnifield	Art Unit 1645	Page 2 of 3

**U.S. PATENT DOCUMENTS**

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	A	US-			
	B	US-			
	C	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

**FOREIGN PATENT DOCUMENTS**

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

**NON-PATENT DOCUMENTS**

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	Greenwood et al, Lancet, April 2005, 3665:1487-1498
	V	Allouche et al, Am. J. Trop. Med. Hyg., 2003, 68/1:97-101
	W	Pinder et al, Clin. Exp. Immunol., 2004:135:286-293
	X	Heppner et al, Vaccine, 2005, 23:2243-2250

\*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)  
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

<b>Notice of References Cited</b>	Application/Control No. 10/789,758	Applicant(s)/Patent Under Reexamination COHEN ET AL.	
	Examiner N. M. Minnifield	Art Unit 1645	Page 3 of 3

**U.S. PATENT DOCUMENTS**

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	A	US-			
	B	US-			
	C	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

**FOREIGN PATENT DOCUMENTS**

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

**NON-PATENT DOCUMENTS**

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	Sun et al, J. Immunology, 2003, 171:6961-6967
	V	Heppner et al, In: New Generation Vaccines, editor Levine et al, 2004, 3 <sup>rd</sup> Edition, pp. 851-59
	W	Burchmore, current Opinino in Anti-Infectious Investigational Drugs, 2000, 2/1:83-87
	X	

\*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)  
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.